Loading
HKSEHealthcareBiotechnology
Latest quote
HK$61.75
+HK$3.75 · +6.47%
Biocytogen Pharmaceuticals (Beijing) Co., Ltd., established in 2009 with its main office in Beijing, China, operates as a global biotechnology firm. Its core business involves the international research and development of antibody-based treatments. The company's drug development portfolio currently features a dozen key product candidates; specifically, two are actively progressing through multi-regional Phase II clinical trials, while another pair is in Phase I clinical assessments. Their therapeutic focus spans critical health areas such as oncology, autoimmune disorders, inflammatory conditions, metabolic diseases, and other ailments. Supporting these pharmaceutical ventures, the broader Beijing Biocytogen Co., Ltd. group, which commenced operations in 2008, also in Beijing, specializes in the creation and large-scale distribution of genetically modified animal models. This group provides comprehensive preclinical research services, leveraging its expertise in advanced gene-humanized models, patient-derived xenograft (PDX) models, and human immune system reconstituted models. Their extensive catalog includes a diverse array of specialized gene-edited mice and rats – for example, B-NDG mice, various Cre and knockout (KO) lines (like B-p53 KO and B-ApoE KO), knock-in (KI) models, B-hFcgrt (FcRn) mice, in addition to genome-edited human embryonic stem cells (hESC) and luciferase-reporter stable tumor cell lines. Furthermore, this overarching Biocytogen entity has cultivated an advanced platform dedicated to antibody discovery and development. It offers specialized pharmacology services across vital domains including tumor immunology, general oncology, autoimmune research, and both in vivo and in vitro pharmacological evaluations. The group also makes its products accessible through online sales channels. Beyond its primary location in Beijing, China, the company maintains additional facilities in Haimen, Jiangsu, and Shanghai, China, as well alongside international branches in Heidelberg, Germany, and Boston, United States.
Latest quote
HK$61.75
+HK$3.75 · +6.47%
Regular session · HKT · Market data may be delayed.
Biocytogen Pharmaceuticals (Beijing) Co., Ltd., established in 2009 with its main office in Beijing, China, operates as a global biotechnology firm. Its core business involves the international research and development of antibody-based treatments. The company's drug development portfolio currently features a dozen key product candidates; specifically, two are actively progressing through multi-regional Phase II clinical trials, while another pair is in Phase I clinical assessments. Their therapeutic focus spans critical health areas such as oncology, autoimmune disorders, inflammatory conditions, metabolic diseases, and other ailments. Supporting these pharmaceutical ventures, the broader Beijing Biocytogen Co., Ltd. group, which commenced operations in 2008, also in Beijing, specializes in the creation and large-scale distribution of genetically modified animal models. This group provides comprehensive preclinical research services, leveraging its expertise in advanced gene-humanized models, patient-derived xenograft (PDX) models, and human immune system reconstituted models. Their extensive catalog includes a diverse array of specialized gene-edited mice and rats – for example, B-NDG mice, various Cre and knockout (KO) lines (like B-p53 KO and B-ApoE KO), knock-in (KI) models, B-hFcgrt (FcRn) mice, in addition to genome-edited human embryonic stem cells (hESC) and luciferase-reporter stable tumor cell lines. Furthermore, this overarching Biocytogen entity has cultivated an advanced platform dedicated to antibody discovery and development. It offers specialized pharmacology services across vital domains including tumor immunology, general oncology, autoimmune research, and both in vivo and in vitro pharmacological evaluations. The group also makes its products accessible through online sales channels. Beyond its primary location in Beijing, China, the company maintains additional facilities in Haimen, Jiangsu, and Shanghai, China, as well alongside international branches in Heidelberg, Germany, and Boston, United States.
Day range
Current HK$61.75
52-week range
Current HK$61.75
Regular session · HKT · Market data may be delayed.
Biocytogen Pharmaceuticals (Beijing) Co., Ltd., established in 2009 with its main office in Beijing, China, operates as a global biotechnology firm. Its core business involves the international research and development of antibody-based treatments. The company's drug development portfolio currently features a dozen key product candidates; specifically, two are actively progressing through multi-regional Phase II clinical trials, while another pair is in Phase I clinical assessments. Their therapeutic focus spans critical health areas such as oncology, autoimmune disorders, inflammatory conditions, metabolic diseases, and other ailments. Supporting these pharmaceutical ventures, the broader Beijing Biocytogen Co., Ltd. group, which commenced operations in 2008, also in Beijing, specializes in the creation and large-scale distribution of genetically modified animal models. This group provides comprehensive preclinical research services, leveraging its expertise in advanced gene-humanized models, patient-derived xenograft (PDX) models, and human immune system reconstituted models. Their extensive catalog includes a diverse array of specialized gene-edited mice and rats – for example, B-NDG mice, various Cre and knockout (KO) lines (like B-p53 KO and B-ApoE KO), knock-in (KI) models, B-hFcgrt (FcRn) mice, in addition to genome-edited human embryonic stem cells (hESC) and luciferase-reporter stable tumor cell lines. Furthermore, this overarching Biocytogen entity has cultivated an advanced platform dedicated to antibody discovery and development. It offers specialized pharmacology services across vital domains including tumor immunology, general oncology, autoimmune research, and both in vivo and in vitro pharmacological evaluations. The group also makes its products accessible through online sales channels. Beyond its primary location in Beijing, China, the company maintains additional facilities in Haimen, Jiangsu, and Shanghai, China, as well alongside international branches in Heidelberg, Germany, and Boston, United States.
Day range
Current HK$61.75
52-week range
Current HK$61.75
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (CNY) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 1.38B CNY | 980.45M CNY | 716.91M CNY | 533.88M CNY | 354.56M CNY |
| Cost of goods sold | 333.22M CNY | 218.94M CNY | 210.88M CNY | 142.13M CNY | 107.12M CNY |
| Gross profit | 1.05B CNY | 761.52M CNY | 506.03M CNY | 391.75M CNY | 247.44M CNY |
| Research and development | 438.05M CNY | 323.93M CNY | 474.37M CNY | 699.17M CNY | 558.49M CNY |
| Selling, general, and administrative | 400.45M CNY | 311.35M CNY | 349.09M CNY | 313.66M CNY | 83.39M CNY |
| Operating expenses | 766.99M CNY | 597.15M CNY | 776.32M CNY | 997.75M CNY | 772.89M CNY |
| Interest income | 4.27M CNY | 5.9M CNY | 10.16M CNY | 2.17M CNY | 12.51M CNY |
| Interest expense | 71M CNY | 91.68M CNY | 99.84M CNY | 56.14M CNY | 39.43M CNY |
| Depreciation and amortization | 160.46M CNY | 169.18M CNY | 182.45M CNY | 138.74M CNY | 128.1M CNY |
| Operating income | 278.6M CNY | 164.37M CNY | −270.29M CNY | −530.44M CNY | −505.82M CNY |
| Net income | 173.2M CNY | 33.54M CNY | −382.95M CNY | −602.16M CNY | −545.58M CNY |
Company facts updated Sep 8, 2026.
Recent quarterly results
Recent quarterly results
Funds reporting this stock among their holdings, ordered by reported position size.
State Street SPDR S&P Emerging Markets Small Cap ETFEWX298.65K0.04%680.67M USD0.65%$74.065+0.75%
Avantis Emerging Markets Equity ETFAVEM139.9K—28.73B USD0.33%$96.81+1.52%
Dimensional - Emerging Core Equity Market ETFDFAE65.69K0.00%10.16B USD0.29%$40.57+1.45%
State Street SPDR S&P China ETFGXC44.15K0.01%465.2M USD0.59%$91.00+0.90%
JPMorgan BetaBuilders Emerging Markets Equity ETFBBEM27.05K0.00%898.19M USD0.15%$78.93+1.70%
Xtrackers Emerging Markets Carbon Reduction and Climate Improvers ETFEMCR7.73K0.01%61.74M USD0.15%$44.50+1.44%
Goldman Sachs MarketBeta Emerging Markets Equity ETFGSEE3.99K—137.42M USD0.45%$69.53930.00%
iShares LifePath Target Date 2050 ETFITDF236.520.00%91.08M USD0.11%$42.64+0.16%State Street SPDR S&P Emerging Markets Small Cap ETFEWXAvantis Emerging Markets Equity ETFAVEMDimensional - Emerging Core Equity Market ETFDFAEState Street SPDR S&P China ETFGXCJPMorgan BetaBuilders Emerging Markets Equity ETFBBEMXtrackers Emerging Markets Carbon Reduction and Climate Improvers ETFEMCRGoldman Sachs MarketBeta Emerging Markets Equity ETFGSEEiShares LifePath Target Date 2050 ETFITDFAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
